Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2004

01-06-2004 | Report

Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial

Authors: Beat Thürlimann, Dagmar Hess, Dieter Köberle, Isabella Senn, Pierluigi Ballabeni, Olivia Pagani, Lucien Perey, Stefan Aebi, Christoph Rochlitz, Aron Goldhirsch

Published in: Breast Cancer Research and Treatment | Issue 3/2004

Login to get access
Metadata
Title
Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial
Authors
Beat Thürlimann
Dagmar Hess
Dieter Köberle
Isabella Senn
Pierluigi Ballabeni
Olivia Pagani
Lucien Perey
Stefan Aebi
Christoph Rochlitz
Aron Goldhirsch
Publication date
01-06-2004
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 3/2004
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/B:BREA.0000025420.78346.f9

Other articles of this Issue 3/2004

Breast Cancer Research and Treatment 3/2004 Go to the issue

Authors Index

Author Index, Volume 85

OriginalPaper

Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 (UGT1A1) and risk of breast cancer

OriginalPaper

Use of complementary and alternative medicine by Chinese women with breast cancer

OriginalPaper

The Full Potential of Breast Cancer Screening Use to Reduce Mortality has not yet been Realized in the United States

OriginalPaper

Determinants of participation in treatment decision-making by older breast cancer patients

OriginalPaper

A Systematic Review of Intraoperative Radiotherapy in Early Breast Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits